



Systematic review on women's values and preferences concerning breast cancer screening and diagnostic services

DOI:
[10.1002/pon.5041](https://doi.org/10.1002/pon.5041)
[10.1002/pon.5041](https://doi.org/10.1002/pon.5041)

Document Version
Accepted author manuscript

[Link to publication record in Manchester Research Explorer](#)

Citation for published version (APA):

Mathioudakis, A. G., Salakari, M., Pytkkanen, L., Saz-Parkinson, Z., Bramesfeld, A., Deandrea, S., Lerda, D., Neamtiu, L., Pardo-Hernandez, H., Solà, I., & Alonso-Coello, P. (2019). Systematic review on women's values and preferences concerning breast cancer screening and diagnostic services. *Psycho-oncology*.
<https://doi.org/10.1002/pon.5041>, <https://doi.org/10.1002/pon.5041>

Published in:
Psycho-oncology

Citing this paper

Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

General rights

Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Takedown policy

If you believe that this document breaches copyright please refer to the University of Manchester's Takedown Procedures [<http://man.ac.uk/04Y6Bo>] or contact uml.scholarlycommunications@manchester.ac.uk providing relevant details, so we can investigate your claim.





Systematic review on women's values and preferences concerning breast cancer screening and diagnostic services

Journal:	<i>Psycho-Oncology</i>
Manuscript ID	PON-18-0860.R2
Wiley - Manuscript type:	Review
Date Submitted by the Author:	21-Feb-2019
Complete List of Authors:	<p>Mathioudakis, Alexander; Iberoamerican Cochrane Centre, Biomedical Research Institute (IIB Sant Pau); University of Manchester, Division of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health</p> <p>Salakari, Minna; Turku university, Public Health</p> <p>Pylkkanen, Liisa; European Commission Joint Research Centre Ispra Sector; Finnish Medicines Agency Fimea</p> <p>Saz-Parkinson, Zuleika; European Commission Joint Research Centre Ispra Sector,</p> <p>Bramesfeld, Anke; European Commission Joint Research Centre Ispra Sector; Medizinische Hochschule Hannover, Institute for Epidemiology Social Medicine and Health System Research</p> <p>Deandrea, Silvia; European Commission Joint Research Centre Ispra Sector; Current address: Health Protection Agency – Metropolitan city of Milan, Italy</p> <p>Lerda, Donata; European Commission Joint Research Centre Ispra Sector</p> <p>Neamtiu, Luciana; European Commission Joint Research Centre Ispra Sector</p> <p>Pardo-Hernandez, Hector; Iberoamerican Cochrane Centre, Biomedical Research Institute (IIB Sant Pau); CIBER de Epidemiología y Salud Pública (CIBERESP)</p> <p>Solà, Ivan; Iberoamerican Cochrane Centre, Biomedical Research Institute (IIB Sant Pau); CIBER de Epidemiología y Salud Pública (CIBERESP)</p> <p>Alonso-Coello, Pablo; Iberoamerican Cochrane Centre, Biomedical Research Institute (IIB Sant Pau); CIBER de Epidemiología y Salud Pública (CIBERESP)</p>
Keywords:	breast cancer, diagnostic services, patient-centered care, patient preference, practice guideline, screening, cancer, oncology



Systematic review on women's values and preferences concerning breast cancer screening and diagnostic services

Alexander G. Mathioudakis^{1,2}, Minna Salakari³, Liisa Pylkkanen^{4,5}, Zuleika Saz-Parkinson^{4*}, Anke Bramesfeld^{4,6}, Silvia Deandrea^{4,7}, Donata Lerda⁴, Luciana Neamtiu⁴, Hector Pardo-Hernandez^{1,8}, Ivan Solà^{1,8}, Pablo Alonso-Coello^{1,8}

¹Iberoamerican Cochrane Centre, Biomedical Research Institute (IIB Sant Pau), Barcelona, Spain

² Division of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

³ Department of Public Health, Faculty of Medicine, University of Turku, Turku, Finland

⁴ European Commission, Joint Research Centre, Ispra, Italy

⁵ Finnish Medicines Agency Fimea, Turku, Finland

⁶ Institute for Epidemiology Social Medicine and Health System Research, Hanover Medical School. Hannover, Germany

⁷ Current address: Health Protection Agency – Metropolitan city of Milan, Italy

⁸ CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.

Alexander Mathioudakis and Minna Salakari are equally contributing first authors.

*Corresponding author

Zuleika Saz-Parkinson

European Commission, Joint Research Centre

Via E. Fermi, 2749. TP127

I-21027 Ispra (VA), Italy

zuleika.saz-parkinson@ec.europa.eu, Phone: +39 0332 789131

This manuscript has not been published in any other journal, and has not been submitted for publication to any other journal. The manuscript has been read and approved by all authors.

Abstract

Background: There is still lack of consensus on the benefit-harm balance of breast cancer screening. In this scenario women's values and preferences are crucial for developing health related recommendations. In the context of the European Commission Initiative on Breast Cancer, we conducted a systematic review to inform *the European Breast Guidelines*.

Methods: We searched Medline and included primary studies assessing women's values and preferences regarding breast cancer screening and diagnosis decision making. We used a thematic approach to synthesise relevant data. The quality of evidence was determined with GRADE, including GRADE CERQual for qualitative research.

Results: We included 22 individual studies. Women were willing to accept the psychological and physical burden of breast cancer screening and a significant risk of overdiagnosis and false-positive mammography findings, in return for the benefit of earlier diagnosis. The anxiety engendered by the delay in getting results of diagnostic tests was highlighted as a significant burden, emphasising the need for rapid and efficient screening services, and clear and efficient communication. The confidence in the findings was low to moderate for screening and moderate for diagnosis, predominantly due to methodological limitations, lack of adequate understanding of the outcomes by participants, and indirectness.

Conclusions: Women value more the possibility of an earlier diagnosis over the risks of a false positive result or overdiagnosis. Concerns remain that women may not understand the concept of overdiagnosis. Women highly value time efficient screening processes and rapid result delivery, and will accept some discomfort for the peace of mind screening may provide.

Key words: breast cancer, diagnostic services, patient-centered care, patient preference, practice guideline, screening, cancer, oncology.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Breast cancer is the most common cancer in women and one of the leading causes of all cancer deaths both in Europe and worldwide¹. Breast cancer screening with mammography, the only population-based method for the early detection of breast cancer currently used, has been shown to reduce breast cancer mortality in women aged 50–74 years² and is widely implemented in most European countries³. However, mammography screening is also associated with potential important undesirable effects, including overdiagnosis, and hence overtreatment, and false positive mammography results⁴. False-positive mammography findings may cause psychological distress⁵. The balance between benefits and harms of screening becomes less favourable after 74 years of age and at 90, harms are considered to outweigh benefits, largely as a consequence of overdiagnosis⁶. There is still a lack of consensus on the benefit-harm balance of breast cancer screening thus underlining the need for women to receive balanced and adequate information in order to make informed decisions concerning their participation in screening programmes.

The European Commission Initiative on Breast Cancer (ECIBC) (<http://ecibc.jrc.ec.europa.eu/>) uses the GRADE approach when formulating recommendations for breast cancer screening and diagnosis. This includes the use of Evidence to Decision (EtD) frameworks when moving from evidence to recommendations⁷. The EtD frameworks provide an explicit and transparent system for decision making that can help ensure all important criteria, informed by the best available research evidence, needed to make a decision are considered. One of these criteria is how those affected by a recommendation value the main desirable and undesirable outcomes of the interventions considered. In the case of recommendations on breast cancer screening, this means considering women's values and preferences regarding potential consequences of participating in screening.

Women's values and preferences refer to the relative weight those affected by a recommendation place on the different outcomes, such as the potential benefits, harms, costs, limitations, and inconveniences of the available interventions or management options⁸. Inclusion of women's values in the screening decision making process has been proposed for decades now⁹, but its implementation is still suboptimal. GRADE's EtD frameworks provide guidance on how to incorporate women's values and preferences while drafting clinical recommendations. This systematic review was thus conducted to inform ECIBC's clinical recommendations' development process.

Methods

Design

1
2
3 A systematic literature review, following standard Cochrane Collaboration methodology¹⁰, was
4 performed to address the following question: What are the values and preferences of women regarding
5 decision making on breast cancer screening and diagnosis. The review protocol is registered in PROSPERO
6 (https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=41487).
7
8
9

10 11 12 ***Search strategy and Selection criteria***

13
14 Medline (assessed through Ovid) was searched using terms regarding breast neoplasm/cancer;
15 screening; diagnosis; different screening and diagnosis outcomes; values, and preferences (complete search
16 strategy in **Appendix 1**). As a source for individual studies, systematic reviews with no time restrictions
17 were searched. For primary studies, publications from 2006 until the end of June 2018 were included. Only
18 studies in English were included.
19
20
21

22
23 Only studies examining women's preferences for breast cancer screening versus no screening or about
24 the potentially available breast cancer diagnostic alternatives, studies evaluating how women value breast
25 cancer screening and diagnosis outcomes, and those examining the choices women facing a breast cancer
26 screening or diagnostic decision make, when informed about the expected desirable and undesirable
27 outcomes, were included. We excluded studies restricted to women's knowledge, views, behaviours,
28 perceptions, attitudes and expectations regarding breast cancer screening and diagnosis. We also excluded
29 those conducted in countries outside the Organisation for Economic Co-operation and Development
30 (OECD), or those focusing exclusively on minorities from geographic regions outside Europe.
31
32
33
34
35
36
37
38

39 ***Screening and data collection***

40
41 One reviewer screened the search results based on title and abstract. Two reviewers independently
42 confirmed eligibility of relevant articles based on the full text, and disagreement between researchers was
43 solved by a third reviewer. One reviewer extracted the main characteristics and main findings of the
44 included studies in a tabular format. Another reviewer checked the extracted data for accuracy. The
45 synthesis of the results is described narratively, and is based on the identification and grouping of themes
46 reported in the included studies.
47
48
49

50
51 Risk of bias assessment was carried out using the domains suggested in the GRADE approach for
52 quantitative studies¹¹, and the Critical Appraisal Skills Programme (CASP) checklist¹² for qualitative studies.
53 The confidence (quality or certainty) of the evidence was rated from high to very low considering the
54 standard GRADE domains for quantitative data¹⁰. For qualitative studies, the CERQual (Confidence in the
55 Evidence from Reviews of Qualitative Research) approach was used¹³. The results of the systematic review
56
57
58
59
60

1
2
3 were reported according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-
4 Analyses) statement¹⁴.
5
6
7

8 9 **Results**

10
11 The search yielded 5,063 unique references, of which 96 were deemed potentially eligible for inclusion,
12 based on initial screening of titles and abstracts. After full text appraisal, 22 individual studies (15 on
13 screening and seven on diagnosis) involving 12,174 women were included. The PRISMA flowchart is
14 presented in **Figure 1**. A tabular summary of the findings and rating of certainty of evidence is presented in
15 **Table 1**. Evidence profiles including main findings and certainty of evidence, for both screening and
16 diagnosis are included in **Appendix 2**.
17
18
19
20
21

22 **Screening**

23
24 We identified the following main themes that contribute to how women value the main outcomes of
25 screening: risk of overdiagnosis and false positive screening results, burden of breast cancer screening, and
26 challenges elderly women face when making a decision to participate in screening programmes.
27
28
29
30

31 **Overdiagnosis**

32
33 Five studies, four conducted in Europe^{15,16,17,18} and one in Australia¹⁹, evaluated women's knowledge and
34 acceptability of the risk of overdiagnosis. Results revealed limited awareness of the risk of overdiagnosis
35 among women. Only 29% and 53% of participants in two population-based surveys, conducted in the UK,
36 were aware of the concept of overdiagnosis^{16,18}. In a study from Spain, only 10% of women had adequate
37 knowledge about the implications of being overdiagnosed¹⁵.
38
39
40
41

42 Four studies^{15,17,18,19} assessed the impact exposure to information concerning overdiagnosis has on
43 women of screening age. Information about overdiagnosis and its implications triggered different
44 immediate reactions among participants. These included surprise and concern regarding the undesirable
45 psychological and physical consequences, as well as defensive reactions and mistrust of the investigators'
46 motives. On the one hand, women considered it would be appropriate and fair to provide adequate
47 information regarding overdiagnosis to women invited for screening but, on the other, they were
48 concerned this information may cause confusion and deter women from participating.
49
50
51
52
53

54 Two studies evaluated the impact information concerning overdiagnosis had on women's intention to
55 participate in screening^{17,18}. Ninety per cent of participants answered they would probably or definitely
56 attend screening in the future. Only seven per cent, especially women below the recommended screening
57 age, actually showed a decrease in screening intention¹⁸.
58
59
60

1
2
3 Two studies evaluated the rate of overdiagnosis that women were willing to accept^{16,19}. On the one
4 hand, a survey showed they were willing to accept 15% and 31% overdiagnosis for an expected benefit of
5 10% and 50% reduction in cancer specific mortality, respectively¹⁶. On the other hand, a focus group study,
6 showed that a rate of 1-10% of overdiagnosis was perceived as completely acceptable, 30% was perceived
7 as still acceptable by most women, but 50% was considered to be extremely high¹⁹.
8
9

10
11
12 The willingness to accept overdiagnosis was related to socio-demographic factors: those with a higher
13 educational status accepted significantly higher levels of overdiagnosis than those with a lower educational
14 status. Furthermore, women over 50 accepted significantly less overdiagnosis than younger women¹⁶.
15 However, in another study, younger participants interpreted overdiagnosis as a distinctly negative factor,
16 discouraging them from participating in screening¹⁹.
17
18
19

20
21 The confidence in the evidence regarding overdiagnosis was considered low. There were significant
22 concerns regarding some studies about whether women were adequately informed in order to fully
23 understand the extent of the risks and benefits associated with breast cancer screening, and specifically the
24 implications of overdiagnosis. This can be seen, for example, in a cross-sectional study evaluating 510
25 British females, 15% of the participants declared that they were prepared to accept overdiagnosis in the
26 complete population, strongly suggesting that they may have not comprehended the aims of screening and
27 the concept of overdiagnosis¹⁶. Indirectness was an additional limitation in some of the studies, as some
28 studies included adult women of any age, rather than women at screening age.
29
30
31
32
33
34
35
36

37 ***False positive screening results***

38
39 The burden and acceptability of false positive mammography screening results was evaluated in seven
40 studies^{20,21,22,23,24,25,26}. A European cross-sectional study involving 1,018 women from the general population
41 used an online discrete choice experiment survey to elicit patients' preferences regarding false positive
42 results²⁶. Respondents highly valued the possibility of early diagnosis and were prepared to accept
43 unnecessary follow-up appointments as a result of a false positive screening result. In fact, over 60% of
44 participants were prepared to accept a 20% false positive rate for a 3% probability of detecting cancer.
45
46
47
48

49
50 Two longitudinal European studies^{21,22} included a pooled population of 671 patients with false positive
51 screening results, 174 patients diagnosed with breast cancer and 1,363 matched women with negative
52 results. Here, a false positive mammography screening result was associated with consistently greater
53 negative psychosocial consequences compared to a negative result, even three years after final diagnosis.
54 However, a study conducted in the United States²⁵, found only a transient increase in personal anxiety after
55 false positive results, which did not persist at one year after final negative diagnosis was made.
56
57
58
59
60

1
2
3 Four studies assessed women's attitudes and beliefs on the effects of false positive mammograms
4 towards future screening behaviour. Ganott and colleagues²³ reported that, prior to mammography
5 examination, 97% of women believed a false positive result would not deter them from screening. Tosteson
6 et al²⁵ reported that among women with a previous false positive mammography finding, the future
7 screening intention was significantly increased compared to those with a negative mammogram. These
8 findings were confirmed by two qualitative studies including women with false positive mammography
9 results^{20,24}. A significant proportion of women would accept the inconvenience and anxiety associated with
10 a higher recall rate if this implied the possibility to detect breast cancer earlier²³.

11
12 The confidence in the evidence from the cross-sectional studies regarding false positive findings was
13 moderate due to methodological limitations (significant concerns regarding inadequacy of information
14 provided to participants that led to poor understanding of benefits and risks of breast cancer screening).
15 The confidence in the evidence from qualitative studies was low, as there were similar methodological
16 limitations, but also these studies mostly evaluated preferences of women who had already received a false
17 positive result and their preferences may not be representative of the general population of women at
18 screening age. Based on all available evidence, the confidence in the evidence was moderate.

30 **Burden**

31
32 A metasynthesis²⁷ including 21 qualitative studies, assessed barriers for breast cancer screening from
33 the women's perspective. The authors reported several aspects of breast cancer screening that may be
34 burdensome for women including: logistical implications, such as investing time and money to reach the
35 screening site, psychological distress associated with the screening process itself, derived from fear of a
36 positive result, embarrassment, and from not receiving services in line with their cultural and religious
37 beliefs. The confidence in the evidence was moderate being limited by the insufficiency of data and
38 methodological limitations.

46 **Screening decisions among elderly women**

47
48 Two studies in the United States assessed factors that influence the decision of elderly women (aged 80
49 and over) to participate in screening programmes^{28,29}. A qualitative study highlighted a more pronounced
50 variability in elderly women's preferences²⁸. Factors influencing more their decision to be screened
51 included women's perceived individual risk of BC, physician's advice, previous screening habits and
52 experiences with mammography, as well as social and family influences. The most important reasons for
53 declining screening were the decision not to undergo a possible operation given their age, and the
54 discomfort associated with an additional clinical visit²⁸. In a cross-sectional study, women aged 80 and older
55
56
57
58
59
60

1
2
3 who decided not to undergo breast cancer screening, ranked their age and doctor's counselling as the
4 factors mostly influencing their decision²⁹.
5
6
7

8 9 **Diagnosis**

10 11 **Anxiety**

12
13 One of the main themes concerning diagnostic procedures in breast cancer is the avoidable anxiety,
14 mostly due to inadequacy of the information regarding procedures, and the delay in receiving test results.
15 This theme was reported in four cross-sectional studies^{30,31,32,33}, one qualitative study³⁴, and one systematic
16 review³⁵.
17
18
19

20
21 Women highly valued receiving diagnostic results in a timely manner. Twelve per cent of women, who
22 underwent image-guided breast biopsies in the US, were not even satisfied with a one-day waiting time for
23 their results. However, 90% of them found receiving the test results over the phone to be acceptable if that
24 accelerated the process³⁰. A cross-sectional study including women who had previously undergone sentinel
25 node biopsy with intraoperative diagnosis found similar results; ninety-five per cent of participants would
26 choose to undergo the procedure again in the future, in order to have the results earlier³¹. Another cross-
27 sectional study showed that better communication with the radiologist performing the biopsies was
28 associated with lower post-biopsy anxiety³².
29
30
31
32
33

34
35 A systematic review showed that the needs for supportive care concerning diagnosis touch upon many
36 domains, which cluster around psychological and information needs. These needs are influenced by
37 individual clinical, demographic, emotional, psychological, or psychosocial characteristics of subjects³⁵.
38 Finally, one study, including only women aged 60 and over, provided information on the benefits of a
39 decision aid³³. The authors did not find any significant differences in decisional support needs based on age
40 at diagnosis, education level, ethnicity, or presence of co-morbidities. Approximately 90% of women
41 indicated they had received a high level of support during their cancer diagnosis. However, the desire for
42 additional educational resources such as worksheets, consultation summaries, or workbooks to assist
43 treatment decisions was highlighted. The overall confidence in these findings concerning anxiety is
44 moderate because of inadequacy of data.
45
46
47
48
49
50
51
52

53 54 **Inconvenience**

55
56 As part of a trial in Australia, a cross-sectional study with 49 women assessed their experience with
57 contrast enhanced spectral mammography (CESM) compared with contrast enhanced MRI (CEMRI) during
58 preoperative breast cancer staging³⁶. Significantly higher overall preference towards CESM was shown, with
59 faster procedure time, greater comfort and lower noise level cited as the commonest reasons. Participants
60

1
2
3 also reported significantly lower rates of anxiety during CESM compared with CEMRI. The overall
4 confidence in these findings is moderate because of inadequacy of data.
5
6
7

8 **Discussion and Conclusions**

9 ***Main findings***

10
11
12 Our review shows that women place a low value on the psychosocial and physical effects of
13 overdiagnosis and false positive mammography screening results, as well on the inconvenience and burden
14 associated with it. Women generally consider these undesirable effects acceptable, recognising the
15 potential benefits of breast cancer screening. However, the confidence in the evidence supporting these
16 findings is low to moderate, due to methodological limitations. Regarding diagnosis, women highly
17 appreciate avoiding anxiety caused by delays in the receipt of results or suboptimal communication with
18 healthcare professionals. They also appear to value faster procedures over the inconvenience associated
19 with them.
20
21
22
23
24
25
26
27
28

29 ***Our results in the context of previous results***

30 Overdiagnosis

31
32 The level of overdiagnosis that women were willing to accept was relatively high; up to 30%^{16,19}. The
33 most commonly reported estimates of overdiagnosis from screening programmes are around 10% and vary
34 widely⁴. Thus the level of overdiagnosis women were willing to accept was on the high end of the estimated
35 average figures. The high rates of overdiagnosis women were willing to accept could put into question
36 whether the concept was really understood by study participants. According to our review, women's
37 knowledge and understanding concerning overdiagnosis was variable, and in general limited, with only
38 about 30-50% of women being aware of the concept, and only 10% having adequate knowledge about its
39 implications. Results from a recently published study from the UK revealed that almost one third of
40 participants reported having previously encountered the term overdiagnosis, but responses often indicated
41 they had very limited knowledge about its implications³⁷.
42
43
44
45
46
47
48
49
50

51 Women appear to overestimate the benefits of mammography screening. Up to 70% of women
52 overestimated the possibility of having breast cancer detected during screening²³. The fear of getting breast
53 cancer may also lead women to be willing to accept a higher level of overdiagnosis. Population-based
54 studies have consistently shown that between a quarter to a half of the general population worry to some
55 extent about getting some type of cancer, and 5%-10% experience extreme worry³⁸. Altogether these
56 findings may partially explain the high levels of overdiagnosis women were willing to accept, and also
57
58
59
60

1
2
3 underlines the importance of providing women with balanced information concerning the benefits and
4 harms of breast cancer screening.
5
6
7

8 9 False positive findings

10 European studies show that false positive screening results were associated with long-term negative
11 psychosocial consequences^{20,21,22}, whereas a US study showed only a transient increase in anxiety²⁵. These
12 conflicting results may be related to the different instruments used to measure anxiety. European studies
13 used a screening-specific validated questionnaire 'Consequences of Breast Cancer Screening' specifically
14 developed to assess the long term psychosocial consequences of false-positive mammography screening,
15 while the US study used the 6 question short-form (STAI-6) of the Spielberger State-Trait Anxiety Inventory
16 (STAI) instrument focusing on measurement of general anxiety. Previous studies have shown inconsistent
17 results concerning psychosocial consequences of false positive results, with some women showing
18 persistent and others only transient anxiety³⁹. A systematic review focusing on the UK population reported
19 that receiving a false positive screening mammogram caused breast cancer-specific psychological distress
20 that may endure up to 3 years, and the degree of distress appears to be related to the level of invasiveness
21 of the assessment procedure³⁴. False positive results may have substantial other impacts on women's
22 health behaviour and well-being. Women with false positive findings have been shown to make a greater
23 use of healthcare services, and have reported lower quality of life than those without false positive
24 findings⁴⁰.
25
26
27
28
29
30
31
32
33
34
35

36 Healthy women at screening age were prepared to accept a high risk of false positive screening results
37 in order to detect breast cancer early. Irrespective of false positive findings, the screening intention
38 remained high, and was even higher among those with a false positive result compared to those with a
39 negative result. Despite significant psychosocial burden caused by false positive screening results, women
40 acknowledge the value of mammography screening. Our results are consistent with another recent
41 systematic review and meta-synthesis by Health Care Ontario, assessing the burden of false-positive and
42 false-negative results and their impact on women's screening intentions⁴¹.
43
44
45
46
47
48

49 Screening decision among elderly women

50
51 Elderly women's preferences regarding breast cancer screening were more heterogeneous. This is
52 consistent with the decreased benefit to risk ratio that these women face⁴². For these reasons, screening of
53 elderly women is not recommended by the majority of available guidelines⁴².
54
55
56
57

58 Diagnostic procedures

59
60

1
2
3 The importance of the quick receipt of diagnostic results has been previously emphasised in several
4 studies^{43,44}. A very high number of women would choose to undergo the diagnostic procedure again in the
5 future in order to have the results earlier³¹. A substantial proportion of women are also willing to accept
6 the inconvenience and anxiety associated with a higher recall rate if it results in earlier breast cancer
7 detection²³. Altogether these findings show that women appear to value more the possibility of an earlier
8 and accurate detection of cancer over the inconvenience and anxiety associated with the diagnostic
9 process itself.

10
11
12
13
14
15 Our results are in agreement with Pahade and coworkers⁴⁵ who have shown that most patients showed
16 decreased anxiety after receiving the examination results from the radiologist. Although it is generally
17 assumed in clinical practice that the best way for patients to receive diagnostic results is to personally
18 discuss them with a qualified professional, Brandon and colleagues reported that most women (90%) found
19 it acceptable to receive the results even over the phone²⁹. This finding can also partially explain the higher
20 value women place on fast delivery of test results over the method chosen to communicate them.

27 28 ***Study limitations***

29 Our review has several strengths. To the best of our knowledge, this is the first systematic review
30 focusing specifically on women's values and preferences about breast cancer screening and diagnostic
31 services. In our evaluation we applied rigorous methods, including the GRADE approach and CERQual
32 methodology for evidence synthesis and quality evaluation of qualitative results.

33
34
35
36 The main limitation of our findings relates to the methodological limitations of the included studies.
37 More specifically, we are not confident that the participants of several of the included studies received
38 balanced information in order to understand complex concepts, such as overdiagnosis. Our study is also
39 limited by the relatively small number of studies and small sample size in some of them. Another limitation
40 is that we only included studies published in English. However, the included studies evaluated a wide
41 variety of populations and countries so we do not believe this limits the generalisation of our findings. The
42 restriction of the search to the last 10 years for primary studies may have also limited our findings, but we
43 are confident that the most important outcomes, such as overdiagnosis, have been mostly studied within
44 this period. The inclusion of previous systematic reviews also limits these concerns. In addition, more
45 recent studies are likely to be more relevant because diagnostic and therapeutic options and outcomes of
46 breast cancer have significantly changed over the last decade.

56 57 ***Clinical implications***

58
59
60

1
2
3 The low-to-moderate quality of the evidence for breast cancer screening and moderate quality evidence
4 for breast cancer diagnosis underlines the need to carry out more well-designed studies on women's values
5 and preferences, including also minorities, women with disabilities, with different cultural, religious,
6 educational and economic backgrounds. Such studies would provide valuable data to panels developing
7 clinical or public health recommendations, as well as to policy-makers when making coverage or public
8 health decisions.
9
10
11
12

13
14 Healthcare community should focus on providing clear, adequate and balanced information on the
15 benefits and risks of breast cancer screening to ensure informed participation. In this context, the use of
16 decision aids could be helpful⁴⁶. A particular emphasis should be made on the communication of
17 overdiagnosis, which was poorly understood based on our findings. Clinicians should also be encouraged to
18 improve their communication skills, and healthcare systems to provide adequate and timely information
19 about test results.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Ethical background

The European Commission Initiative on Breast Cancer (ECIBC) (<http://ecibc.jrc.ec.europa.eu/>) uses the GRADE approach when formulating recommendations for breast cancer screening and diagnosis. This includes the use of Evidence to Decision (EtD) frameworks that provide an explicit and transparent system for decision making to ensure all important criteria needed to make a decision are considered. One of these criteria is how those affected by a recommendation value the main desirable and undesirable outcomes of the interventions considered. This systematic review was thus conducted to inform ECIBC's clinical recommendations' development process.

Neither patient consent nor ethical committee approval was necessary as, due to the type of work presented (a systematic review of the literature), this is not needed.

Conflict of interests

AM, HPH, IS and PAC were working at the time this work was carried out for Iberoamerican Cochrane Collaboration which received payments from the European Commission to develop the systematic reviews informing the ECIBC recommendations.

LP, ZSP, AB, SD, DL and LN were working, or are working, for the European Commission, JRC.

No other interests are declared.

Funding

The systematic review was carried out by Iberoamerican Cochrane Collaboration under Framework contract 443094 for procurement of services between European Commission Joint Research Centre and Asociación Colaboración Cochrane Iberoamericana. Administrative Arrangement SANCO/2012/C – 17.030600/12//SI2.635313 between the European Commission Directorate-General Health and Food Safety and the Directorate-General Joint Research Centre.

A.G. Mathioudakis was funded by a Fellowship in Guidelines Methodology by the European Respiratory Society (MTF 2015-01).

Authors' contributions

Alexander Mathioudakis, Ivan Solà and Pablo Alonso-Coello were responsible for conducting the systematic review, including the interpretation of the results and the drafting of the full report of the systematic review (available upon request). Alexander Mathioudakis and Hector Pardo-Hernandez conducted the search and data extraction. Liisa Pylkkanen, Silvia Deandrea, and Donata Lerda contributed to the definition of the research protocol, and provided comments to the preliminary results. Alexander Mathioudakis, Pablo Alonso-Coello, Minna Salakari and Liisa Pylkkänen drafted the first version of the article. All authors contributed to the interpretation and reporting of the results and provided comments on subsequent versions of the article. All authors read and approved the final manuscript prior submission.

For Peer Review

Table 1. Tabulated summary of findings and rating of the confidence in the evidence about screening

Review Finding	Confidence in the Evidence	Explanation	Studies Contributing to the Review Finding
<p><u>False positives</u></p> <p>Women significantly place a low value on the psychosocial and physical effects of false positive results. However, women consider false positive results an acceptable consequence of mammographic breast cancer screening.</p>	Moderate confidence	There are significant concerns regarding women's lack of understanding about breast cancer screening, especially the undesirable effects. In addition, the adequacy of the information provided to the breast cancer participants, which would help them take an informed decision, seems to be inadequate.	Bolejko 2014, Bolejko 2015, Ganott 2006, Brodersen 2013, Thompson 2015, Tosteson 2014, Vass 2018
<p><u>Overdiagnosis</u></p> <p>Women significantly place a low value on the psychosocial and physical effects of overdiagnosis. However, women generally seem to consider</p>	Low confidence	There are significant concerns regarding women's lack of understanding about breast cancer screening, especially the undesirable effects. For instance, Van den Bruel et al reported that 10-14% of the participants accepted overdetection	Baena-Cañada 2014, Hersch 2013, Van den Bruel 2015, Waller 2013, Waller

<p>1 2 3 these undesirable effects 4 5 acceptable given their 6 7 knowledge about the 8 9 potential desirable 10 11 consequences of breast 12 13 cancer screening. 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29</p>		<p>in the overall population, implying that they did not comprehend the aims of screening and the concept of overdiagnosis. In addition, the information provided to breast cancer participants, which would help them take an informed decision, seems to be inadequate. Also, indirectness is a limitation of some of the included studies, which assessed adult women of any age, rather than women of screening age.</p>	<p>2014</p>
--	--	---	-------------

Peer Review

References

- 1 Ferlay J, Forman D, Mathers CD, Bray F. Breast and cervical cancer in 187 countries between 1980 and 2010. *Lancet*. 2012;379(9824):1390-1. doi: 10.1016/S0140-6736(12)60595-9.
- 2 IARC Handbook. Breast Cancer Screening. Volume 15. IARC Handbooks of Cancer Prevention, 2016. IARC, Lyon, France.
- 3 Deandrea S, Molina-Barceló A, Uluturk A, Moreno J, Neamtii L, Peiró-Pérez R, Saz-Parkinson Z, Lopez-Alcalde J, Lerda D, Salas D. Presence, characteristics and equity of access to breast cancer screening programmes in 27 European countries in 2010 and 2014. Results from an international survey. *Preventive Medicine* 2016; 91:250-263
- 4 Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. 2013. The benefits and harms of breast cancer screening: an independent review. *Br J Cancer*. 2013; 108(11):2205-40.
- 5 Salz T, Richman AR, Brewer NT. Meta-analyses of the effect of false-positive mammograms on generic and specific psychosocial outcomes. *Psychooncology* 2010;19:1026-34.
- 6 van Ravesteyn NT, Stout NK, Schechter CB, Heijnsdijk EA, Alagoz O, Trentham-Dietz A, Mandelblatt JS, de Koning HJ. Benefits and harms of mammography screening after age 74 years: model estimates of overdiagnosis. *J Natl Cancer Inst*. 2015 May 6;107(7)
- 7 Schünemann HJ, Mustafa R, Brozek J, Santesso N, Alonso-Coello P, Guyatt G, et al. 2016. GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health. *J Clin Epidemiol*. 2016;76:89-98.
- 8 Muhlbacher AC, Juhnke C. 2013. Patient preferences versus physicians' judgement: does it make a difference in healthcare decision making? *Appl Health Econ Health Policy* 2013;11(3):163-180.
- 9 Pellissier JM, Venta ER. 1996. Introducing patient values into the decision making process for breast cancer screening. *Women Health*. 1996;24(4):47-67.
- 10 Higgins J, Green S. 2011. *Cochrane Handbook for Systematic Reviews of Interventions*.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
-
- ¹¹ Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A: GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. *J Clin Epidemiol* 2011, 64(4):380-2.
- ¹² Critical Appraisal Skills Programme (CASP) 2015. <http://www.casp-uk.net/casp-tools-checklists>
- ¹³ Lewin S, Glenton C, Munthe-Kaas H, Carlsen B, Colvin CJ, Gulmezoglu M, Noyes J, Booth A, Garside R, Rashidian A. Using qualitative evidence in decision making for health and social interventions: an approach to assess confidence in findings from qualitative evidence syntheses (GRADE-CERQual). *PLoS Med* 2015, 12(10):e1001895.
- ¹⁴ Liberati A, Altman D G, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration *BMJ* 2009;339:b2700.
- ¹⁵ Baena-Cañada JM, Rosado-Varela P, Expósito-Álvarez I, González-Guerrero M, Nieto-Vera J, Benítez-Rodríguez E. Women's perceptions of breast cancer screening. Spanish screening programme survey. *Breast*. 2014;23(6):883-8. doi: 10.1016/j.breast.2014.09.010.
- ¹⁶ Van den Bruel A, Jones C, Yang Y, Oke J, Hewitson P. 2015. People's willingness to accept overdetection in cancer screening: population survey. *BMJ*. 2015;350:h980. doi: 10.1136/bmj.h980.
- ¹⁷ Waller J, Douglas E, Whitaker KL, Wardle J. 2013. Women's responses to information about overdiagnosis in the UK breast cancer screening programme: a qualitative study. *BMJ Open*. 2013;3(4). pii: e002703.
- ¹⁸ Waller J, Whitaker KL, Winstanley K, Power E, Wardle J. 2014. A survey study of women's responses to information about overdiagnosis in breast cancer screening in Britain. *Br J Cancer*. 2014;111(9):1831-5.
- ¹⁹ Hersch J, Jansen J, Barratt A, Irwig L, Houssami N, Howard K, Dhillon H, McCaffery K. 2013. Women's views on overdiagnosis in breast cancer screening: a qualitative study. *BMJ*. 2013;346:f158. doi: 10.1136/bmj.f158.
- ²⁰ Bolejko A, Zackrisson S, Hagell P, Wann-Hansson C. 2014. A roller coaster of emotions and sense--coping with the perceived psychosocial consequences of a false-positive screening mammography. *J Clin Nurs*. 2014;23(13-14):2053-62.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
-
- ²¹ Bolejko A, Hagell P, Wann-Hansson C, Zackrisson S. 2015. Prevalence, Long-term Development, and Predictors of Psychosocial Consequences of False-Positive Mammography among Women Attending Population-Based Screening. *Cancer Epidemiol Biomarkers Prev.* 2015;24(9):1388-97.
- ²² Brodersen J, Siersma V. 2013. Long-term psychosocial consequences of false-positive screening mammography – a cohort study with 3-year follow-up. *Annals of Family Medicine* 2013;11(2):106-15.
- ²³ Ganott MA, Sumkin JH, King JL, Klym AH, Catullo VJ, Cohen CS, Gur D. 2006. Screening mammography: do women prefer a higher recall rate given the possibility of earlier detection of cancer? *Radiology.* 2006;238(3):793-800.
- ²⁴ Thompson J, Coleman R, Colwell B, Freeman J, Greenfield D, Holmes K, Mathers N, Reed M. 2013. Levels of distress in breast cancer survivors approaching discharge from routine hospital follow-up. *Psycho-oncology* 2013;22(8):1866-71.
- ²⁵ Tosteson AN, Fryback DG, Hammond CS, Hanna LG, Grove MR, Brown M, Wang Q, Lindfors K, Pisano ED. 2014. Consequences of false-positive screening mammograms. *JAMA Intern Med.* 2014;174(6):954-61.
- ²⁶ Vass CM, Rigby D, Payne K. Investigating the Heterogeneity in Women's Preferences for Breast Screening: Does the Communication of Risk Matter? *Value Health.* 2018 Feb;21(2):219-228.
- ²⁷ Azami-Aghdash S, Ghojzadeh M, Sheyklo SG, Daemi A, Kolahdouzan K, Mohseni M, Moosavi A. 2015. Breast Cancer Screening Barriers from the Womans Perspective: a Meta-synthesis. *Asian Pacific journal of cancer prevention : APJCP* 2015;16(8):3463-71.
- ²⁸ Schonberg MA, Ramanan RA, McCarthy EP, Marcantonio ER. 2006. Decision making and counseling around mammography screening for women aged 80 or older. *Journal of general internal medicine* 2006;21(9):979-85.
- ²⁹ Schonberg MA, McCarthy EP, York M, Davis RB, Marcantonio ER. 2007. Factors influencing elderly women's mammography screening decisions: implications for counseling. *BMC geriatrics* 2007;7:26.
- ³⁰ Brandon CJ, Mullan PB. 2011. Patients' perception of care during image-guided breast biopsy in a rural community breast center: communication matters. *Journal of cancer education: the official journal of the American Association for Cancer Education* 2011;26(1):156-160.

- 1
2
3
4 ³¹ Chicken DW, Sivanadarajah N, Keshtgar MRS. 2007. Patients' view on intraoperative diagnosis of sentinel
5
6 nodes in breast cancer: is it an automatic choice? *International journal of surgery (London, England)*
7
8 2007;5(2):76-80.
9
- 10 ³² Miller LS, Shelby RA, Balmadrid MH, Yoon S, Baker JA, Wildermann L, Soo MS. 2013. Patient anxiety
11
12 before and immediately after imaging-guided breast biopsy procedures: impact of radiologist-patient
13
14 communication. *Journal of the American College of Radiology: JACR* 2013;10(6):423-31.
15
16
- 17 ³³ Presutti R, D'Alimonte L, McGuffin M, Chen H, Chow E, Pignol J-P, Di Prospero L, Doherty M, Kiss A, Wong
18
19 J et al. 2014. Decisional support throughout the cancer journey for older women diagnosed with early stage
20
21 breast cancer: a single institutional study. *Journal of cancer education: the official journal of the American*
22
23 *Association for Cancer Education* 2014;29(1):129-135.
24
25
- 26 ³⁴ Bond M, Pavey T, Welch K, Cooper C, Garside R, Dean S, Hyde CJ. Psychological consequences of false-
27
28 positive screening mammograms in the UK. *Evid Based Med.* 2013;18(2):54-61. doi: 10.1136/eb-2012-
29
30 100608.
31
32
- 33 ³⁵ Fiszer C, Dolbeault S, Sultan S, Brédart A.. Prevalence, intensity, and predictors of the supportive care
34
35 needs of women diagnosed with breast cancer: a systematic review. *Psychooncology.* 2014;23(4):361-74.
36
37
- 38 ³⁶ Hobbs MM, Taylor DB, Buzynski S, Peake RE. 2015. Contrast-enhanced spectral mammography (CESM)
39
40 and contrast enhanced MRI (CEMRI): Patient preferences and tolerance. *Journal of medical imaging and*
41
42 *radiation oncology* 2015;59(3):300-5.
43
44
- 45 ³⁷ Ghanouni A, Meisel SF, Renzi C, et al. Survey of public definitions of the term 'overdiagnosis' in the UK.
46
47 *BMJ Open* 2016;6: e010723. doi:10.1136/bmjopen-2015-010723.
48
- 49 ³⁸ Wrinten C, McGregor LM, Heinrich M, von Wagner C, Waller J, Wardle J, Black GB. What do people fear
50
51 about cancer? A systematic review and meta-synthesis of cancer fears in the general population.
52
53 [Psychooncology.](#) 2017;26(8):1070-9. doi: 10.1002.
54
55
- 56 ³⁹ Nelson HD, Cantor A, Humphrey L, Fu R, Pappas M, Daeges M, Griffin J. Screening for Breast Cancer: A
57
58 Systematic Review to Update the 2009 U.S. Preventive Services Task Force Recommendation. *Evidence*
59
60

1
2
3
4 Syntheses, No.124. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016. Report No.: 14-
5
6 05201-EF-1.

7
8
9 ⁴⁰ van der Steeg A, Keyzer-Dekker C, De Vries J, Roukema JA. Effect of abnormal screening mammogram on
10
11 quality of life. *Br J Surg.* 2011;98(4):537-42. doi: 10.1002/bjs.7371.

12
13 ⁴¹ Health Quality Ontario. Women's Experiences of Inaccurate Breast Cancer Screening Results: A
14
15 Systematic Review and Qualitative Meta-synthesis. *Ont Health Technol Assess Ser.* 2016;16(16):1-22.
16
17 eCollection 2016.

18
19
20 ⁴² Jørgensen KJ, Kalager M, Barratt A, Baines C, Zahl PH, Brodersen J, Harris RP. Overview of guidelines on
21
22 breast screening: Why recommendations differ and what to do about it. *Breast.* 2017 Feb;31:261-269.


23
24 ⁴³ Hislop T, Harris S, Jackson J, Thorne S, Rousseau E, Coldman A, Vestrup J, Wright C, Olivotto I. Satisfaction
25
26 and anxiety for women during investigation of an abnormal screening mammogram. *Breast Cancer Res*
27
28 *Treat.* 2002;76(3):245-54.

29
30
31 ⁴⁴ Molina-Barceló A, Salas Trejo D, Miranda García J. Women's satisfaction with waiting times for further
32
33 investigation in breast cancer screening. *Gac Sanit.* 2011;25(5):357-62.

34
35 ⁴⁵ Pahade J, Couto C, Davis RB, Patel P, Siewert B, Rosen MP. 2012. Reviewing imaging examination results
36
37 with a radiologist immediately after study completion: patient preferences and assessment of feasibility in
38
39 an academic department. *Am J Roentgenol.* 2012;199(4):844-51.

40
41
42 ⁴⁶ Martínez-Alonso M, Carles-Lavila M, Pérez-Lacasta MJ, Pons-Rodríguez A, García M, Rué M. Assessment
43
44 of the effects of decision aids about breast cancer screening: a systematic review and meta-analysis. *BMJ*
45
46 *Open* 2017;7:e016894

Figure 1. PRISMA Flowchart for inclusion and exclusion of the studies



1
2
3 **Appendix 1. Search algorithm and references retrieved**
4
5
6
7

Database and date	
MEDLINE	1 *Breast Neoplasms/di (17240)
Ovid	2 *Breast Neoplasms/ra (6704)
MEDLINE(R) In- Process & Other Non- Indexed	3 breast.ti. (212016) 4 1 or 2 or 3 (218134) 5 *Mass Screening/ (46220)
Citations, Ovid MEDLINE(R) Daily and Ovid	6 Early Detection of Cancer/ (11933) 7 screen*.ti,ab. (534189)
MEDLINE(R) <1946 to Present> 09.12.2015	8 5 or 6 or 7 (546404) 9 4 and 8 (17898) 10 *Mammography/ (15268) 11 mammogra*.ti,ab. (26732) 12 9 or 10 or 11 (38342) 13 diagnos*.ti,ab. (1857062) 14 overdiagnos*.ti,ab. (2622) 15 over diagnos*.ti,ab. (885) 16 over detection.ti,ab. (75) 17 over detection.ti,ab. (67)

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- | | |
|----|---|
| 18 | 13 or 14 or 15 or 16 or 17 (1858213) |
| 19 | 3 and 18 (37972) |
| 20 | 12 or 19 (66766) |
| 21 | *Choice Behavior/ (11911) |
| 22 | *Decision Making/ (31408) |
| 23 | *Attitude to Health/ (38689) |
| 24 | understanding.ti,ab. (554994) |
| 25 | perception*.ti,ab. (171098) |
| 26 | preference*.ti,ab. (106827) |
| 27 | attitude*.ti,ab. (108337) |
| 28 | expectation*.ti,ab. (62344) |
| 29 | (value or values).ti,ab. (1410329) |
| 30 | (view or views).ti,ab. (280091) |
| 31 | informed choice*.ti,ab. (1813) |
| 32 | informed decision*.ti,ab. (4662) |
| 33 | (women* adj5 decision*).ti,ab. (3170) |
| 34 | (screening adj5 decision*).ti,ab. (1777) |
| 35 | 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33
or 34 (2569146) |
| 36 | 20 and 35 (13444) |

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- | | |
|----|--|
| 37 | Qualitative Research/ (25350) |
| 38 | Focus Groups/ (19437) |
| 39 | qualitative.ti,ab. (142495) |
| 40 | interview*.ab. (231234) |
| 41 | focus group*.ti,ab. (26987) |
| 42 | purposive.ab. (4779) |
| 43 | theory.ab. (206388) |
| 44 | grounded theory.ab. (7063) |
| 45 | (mixed adj3 method*).ti,ab. (9327) |
| 46 | meta-ethnograph*.ti,ab. (227) |
| 47 | meta-synthe*.ti,ab. (337) |
| 48 | 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 (547218) |
| 49 | 36 and 48 (1316) |
| 50 | limit 49 to "systematic reviews" (28) |
| 51 | limit 49 to "reviews (best balance of sensitivity and specificity)" (75) |
| 52 | 50 or 51 (85) |
| 53 | 49 not 52 (1231) |
| 54 | 36 not 49 (12128) |
| 55 | exp Decision Support Techniques/ (66253) |
| 56 | (health adj3 utilit*).ti,ab. (2466) |

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- | | |
|----|---|
| 57 | gamble*.ti,ab. (3318) |
| 58 | prospect theor*.ti,ab. (174) |
| 59 | preference score*.ti,ab. (373) |
| 60 | (preference* adj5 elicitat*).ti,ab. (165) |
| 61 | health utilit*.ti,ab. (1362) |
| 62 | (utilit* adj3 (value* or score* or estimate*)).ti,ab. (3224) |
| 63 | (state adj5 utilit*).ti,ab. (773) |
| 64 | health state.ti,ab. (2958) |
| 65 | feeling thermometer*.ti,ab. (54) |
| 66 | best-worst scaling.ti,ab. (63) |
| 67 | standard gamble.ti,ab. (740) |
| 68 | time trade-off.ti,ab. (889) |
| 69 | TTO.ti,ab. (721) |
| 70 | probability trade-off.ti,ab. (16) |
| 71 | 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67
or 68 or 69 or 70 (77125) |
| 72 | 54 and 71 (154) |
| 73 | 54 not 72 (11974) |
| 74 | *Questionnaires/ (33072) |
| 75 | Cross-Sectional Studies/ (209337) |

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	76 (survey or questionnair* or cross-sectional).ti,ab. (784271)
	77 74 or 75 or 76 (858049)
	78 73 and 77 (1486)
	79 limit 78 to "systematic reviews" (29)
	80 limit 78 to "reviews (best balance of sensitivity and specificity)" (50)
	81 79 or 80 (64)
	82 78 not 81 (1422)
	83 73 not 82 (10552)
	84 review.pt. (2087807)
	85 83 and 84 (1226)
	86 52 or 53 or 72 or 81 or 82 or 85 (4144)

For Peer Review



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Appendix 2. Evidence Profiles.

Screening decisions

Quality assessment							Study population and characteristics	Findings	Quality	Studies Contributing to the Review Finding
No. of studies	Study design	Risk of bias/Methodological limitations	Inconsistency/Coherence	Indirectness/Relevance	Imprecision/Adequacy of data	Other considerations				
Overdiagnosis										
3	Cross-sectional studies	serious ¹	none	non serious ²	none	none	3216 adult women	The disutility of overdiagnosis was high among women in the included studies. However, they consider it an acceptable risk of mammographic breast cancer screening.	⊕⊕○○ LOW	Baena-Cañada 2014, Van den Bruel 2015, Waller 2014
2	Qualitative studies	serious ¹	none	none	serious ³	none	90 women of breast screening age		⊕⊕○○ LOW	Hersch 2013, Waller 2013
False positives										
4	Cross-sectional studies	non serious ³	none	none	none	none	1173 women with a false positive mammographic result versus 1424 women with a negative mammographic result.	The disutility of false positive mammographic results was high among women in the included studies. However they	⊕⊕⊕○ MODERATE	Bolejko 2015, Brodersen 2013, Ganott 2006, Tosteson 2014, Vass 2018

2	Qualitative studies	serious ¹	none	Serious ⁵	none	none	53 women who have received a false positive mammographic result.	consider it an acceptable risk of mammographic breast cancer screening.	 LOW	Bolejko 2014, Thompson 2013
Burden associated with breast cancer screening programmes										
1	Systematic review of 21 qualitative studies	non serious ⁵	none	non serious	non serious ⁶	none	1084 women of different ethnicities. USA (8), Iran (3), Jordan (1), Black minority ethnic groups in the UK, Greece (1), Western Cape (1), Malaysia (1), Turkey (1), Spain (1), Chile (1), United Arab Emirates (1).	Logistical implications of breast cancer screening, including time and money expenditure, may be burdensome for women who participate in these screening programs.	 MODERATE	Azami-Aghdash 2015

¹ Concerns regarding adequacy of information given to participants in order to take an informed decision.

² Questionnaires were distributed among adult women in general, rather than women of screening age.

³ Only limited data are available.

⁴ Values of patients who have already received a false positive result were assessed.

⁵ The included studies were subject to minor methodological limitations. Authors do not link findings and the studies they were derived from.

⁶ Only three of the included studies were conducted in Europe. Authors also acknowledge that some of the review findings were highlighted in <25% of the included studies.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Diagnostic decisions

Quality assessment							Study population and characteristics	Findings	Quality	Studies Contributing to the Review Finding
No. of studies	Study design	Risk of bias/Methodological limitations	Inconsistency/Coherence	Indirectness/Relevance	Imprecision/Adequacy of data	Other considerations				
Anxiety										
1	SR of cross sectional studies	None	none	none	serious ¹	none	3056 breast cancer patients.	Patients highly disvalue avoidable anxiety.	⊕⊕⊕○ MODERATE	Fiszer 2014, Brandon 2011, Chicken 2007, Miller 2013, Presutti 2014
4	Cross sectional studies									
Inconvenience										
1	Cross sectional study	None	none	none	serious ¹	none	49 women who underwent both CESM and CEMRI as part of a trial in Australia.	Women highly value comfortable and fast procedure.	⊕⊕⊕○ MODERATE	Hobbs 2015

¹ Inadequate data.



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	P. 1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria; participants; and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	P. 2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	P. 3
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	P. 3
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	P. 3
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	P. 4
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	P. 4
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Appendix 1
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	P. 4
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	P. 4
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	Table 1 p. 15
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	P. 4
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	N/A
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2 for each meta-analysis).	P. 4

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	P. 4
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	N/A
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	P. 5
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	Table 1 P. 5
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	N/A
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	Appendix 2
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	N/A
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see item 15).	Appendix 2
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see item 16]).	N/A
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	P. 9
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	P. 11
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	P. 9-12
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	P. 13

From: Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60